With Ph.D. in 1995 at Chiba University, Minoru Tomizawa is Head of Department of Gastroenterology, National Hospital Organization Shimoshizu Hospital. Major interest of his research is molecular aspects of liver regeneration and hepatocellular carcinoma (HCC). As a gastroenterologist, he performs endoscopic retrograde cholangiopancreatography and endoscopic ultrasonography in addition to radiological diagnosis with ultrasonography, computed tomography, and magnetic resonance imaging. He invented a protocol of differentiation of human induced plruipotent stem (iPS) cells to hepatic progenitor cells within seven days, a feeder-free culture medium of iPS cells. Recently he proposed a medium of selecting human primary hepatocytes from co-culture with iPS cells. Regarding HCC, he has been investigating insulin-like growth factor in search for molecular therapy since his career in National Institutes of Health (Bethesda, MD). Recently Wnt signaling pathway has added his interests. He found frizzled, a receptor of Wnt pathway, is a potential target of molecular therapy to HCC and pancreatic cancer. These results were applied for patents. With his expertise as mentioned above, he published papers covering from basic science to clinical practice as well as book chapters. He serves as an editorial board of basic and clinical journals, and reviews numerous scientific papers. He also serves as Councilor of the Japanese Society for Regenerative Medicine and the Japanese Society of Gastroenterology. He is a member of American Association for the Study of Liver Diseases, International Society for Stem Cell Research, and American Society of Gene & Cell Therapy.